ALK and medullary thyroid gland carcinoma: Additionally, in a phase Ib study (PROFILE 1013; NCT01121588), which enrolled 44 ALK-positive metastatic patients, one individual diagnosed with MTC experienced a PR lasting 16.1 weeks [138].